| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Edgewise Therapeutics, Inc. (EWTX) has 15 insiders with recent SEC Form 4 filings, including 4 buys and 8 sells. EWTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 262.5K | $9.34M | - | |
| Other | 105.0K | $3.74M | - | |
| Dir | 45.1K | $1.61M | - | |
| CEO | 38.6K | $1.37M | - | |
| Dir | 30.0K | $1.07M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | Donovan Joanne M.53 | CMO | Sale+OE | 2,862 | $13.39 | $38,329.05 | -10.1% | +36.5% | - | |
| Aug 12, 2025 | Russell Alan J78 | Chief Scientific Officer | Sale+OE | 1,907 | $13.39 | $25,539.31 | -7.5% | +36.5% | - | |
| May 2, 2025 | Carruthers R Michael51 | Chief Financial Officer | Sale+OE | 1,314 | $16.45 | $21,620.82 | -1.6% | -15.7% | +81.0% | |
| May 2, 2025 | Russell Alan J78 | Chief Scientific Officer | Sale+OE | 1,551 | $16.45 | $25,520.46 | -7.7% | -15.7% | +81.0% | |
| May 2, 2025 | Moore John R45 | General Counsel | Sale+OE | 1,930 | $16.45 | $31,756.61 | -22.8% | -15.7% | +81.0% | |
| May 2, 2025 | Koch Kevin58 | President And CEO | Sale+OE | 4,276 | $16.45 | $70,358.16 | -17.2% | -15.7% | +81.0% | |
| May 2, 2025 | Donovan Joanne M.53 | CMO | Sale+OE | 5,187 | $16.45 | $85,347.94 | -19.4% | -15.7% | +81.0% | |
| May 2, 2025 | Derakhshan Behrad54 | Chief Business Officer | Sale+OE | 1,691 | $16.45 | $27,824.05 | -7.7% | -15.7% | +81.0% | |
| Apr 3, 2025 | Thompson Peter A.65 | Director, 10% Owner | Buy | 496,771 | $20.13 | $10,000,000.23 | +3.4% | -4.2% | +145.4% | |
| Apr 3, 2025 | Orbimed Advisors LLC67 | Director, 10% Owner | Buy | 496,771 | $20.13 | $10,000,000.23 | +3.4% | -4.2% | +145.4% |